Biobank Cycle Collection

Pregnancy Clinical Trial

— BCC  

Official title:

Biobank Cycle Collection Study From Women Trying to Conceive

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05642637
• Other study ID #: PROTOCOL-1388
• Status: Recruiting
• Start date: December 6, 2022
• Est. completion date: September 2024

Study information

• Verified date: December 2023
• Source: SPD Development Company Limited
• Contact: Sarah Weddell
• Phone: 01234 835000
• Email: sarah.weddell[@]spdspark.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study will provide daily urine samples from volunteers who are trying to conceive in order to maintain the SPD biobank.

Study volunteers, seeking to conceive will be provided with a CE marked Clearblue Ovulation product to help them pinpoint their most fertile time and aid conception. All volunteers will provide daily early morning urine samples throughout the study period and keep a study diary of menses and pregnancy test results for up to 3 menstrual cycles.

Urine samples will be received in the clinical laboratory and aliquoted and stored at -80˚C until required.

Description:

The purpose if this study is to maintain the SPD Biobank with urine samples from cycles in which conception occurred and ones where conception did not occur, together with associated sample information including demographic and clinical data e.g. menses days, volunteer age and reproductive hormone concentrations.

Study volunteers, seeking to conceive will be recruited to the study after providing written informed consent. All volunteers will be provided with a CE marked Clearblue Ovulation product to help them pinpoint their most fertile time and aid conception and be required to collect daily early morning urine samples throughout the study until pregnancy is confirmed or their next menstrual period starts. Volunteers will be required to keep a daily diary of menses, sample collection and pregnancy test results. The study will last for up to 3 consecutive menstrual cycles.

Urine samples will be received in the clinical laboratory and will be tested for the presence of hormones related to pregnancy and fertility, then aliquoted and stored in the SPD Biobank at -80˚C until required for product development or evaluation purposes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 260
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Females aged 18 and over actively trying to conceive

• At least 2 regular consecutive cycles since last pregnancy/miscarriage/ stopping breastfeeding or contraception

• Willing to disclose their pregnancy status and provide urine samples.

• Willing to give informed consent and comply with the study procedures

Exclusion Criteria:

• Trying to conceive for >6 months (under 35 years) or > 3 months (35 years and over)

• Has a diagnosis of Polycystic Ovary Syndrome (PCOS)

• Taking medication or has known condition which means they should not get pregnant.

• Currently pregnant or breastfeeding

• Using any treatment which may affect the menstrual cycle (e.g. contraceptive pill)

• Using or has previously used infertility medications or hormone replacement medications containing LH or hCG \ (e.g. Pregnyl®)

• Using or undergoing any other medical treatment for fertility such as ovulation drugs, artificial insemination and assisted fertility such as IVF or ICSI

• Peri-or post-menopausal, e.g. experiencing symptoms: irregular menstrual periods, hot flushes, night sweats, sleep disturbances and/or moods swings

• Abnormal liver or kidney function

• Taking antibiotics containing tetracycline.

• Participated in this study within the last 6 months

Related Conditions & MeSH terms

• Pregnancy

Locations

Country	Name	City	State
United Kingdom	SPD Development Company Ltd	Bedford	Bedfordshire

Sponsors (1)

Lead Sponsor	Collaborator
SPD Development Company Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Collection of daily urine samples from women trying to conceive	Daily samples collected throughout the cycle in which conception occurs	2 years